Download PDF
J Pediatr Infect Dis 2020; 15(01): 011-015
DOI: 10.1055/s-0039-1693484
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Bordetella Pertussis Antibody Levels in DPT/Pentavalent Immunized Preschool Nigerian Children: A Cross-Sectional Study

Glory Ekpo Bassey
1   Department of Paediatrics, University of Calabar and University of Calabar Teaching Hospital, Calabar, Nigeria
,
Emmanuel Eyo Ekanem
1   Department of Paediatrics, University of Calabar and University of Calabar Teaching Hospital, Calabar, Nigeria
,
Henry Chima Okpara
2   Department of Chemical Pathology, University of Calabar and University of Calabar Teaching Hospital, Calabar, Nigeria
,
Komomo Ibor Eyong
1   Department of Paediatrics, University of Calabar and University of Calabar Teaching Hospital, Calabar, Nigeria
› Author Affiliations
Further Information

Publication History

28 November 2018

10 June 2019

Publication Date:
01 August 2019 (online)

    Permissions and Reprints

Abstract

Pertussis is a vaccine-preventable disease and antibodies formed are known to decline with time. The aim of this study was to measure Bordetella pertussis/toxin immunoglobulin G (IgG) antibodies in different age groups of Nigerian children and determine the age at which booster dose may be required. A total of 422 children, aged 6 to 60 months, were tested for the presence of B. pertussis/toxin IgG antibodies by ELISA (enzyme-linked immune sorbent assay). The highest positivity rate was in the 6 to 11 months of age group, while the highest negativity rate was in the age group of 24 to 35 months. We conclude that B. Pertussis/toxin IgG antibodies response is weak in Nigerian children after three doses of DPT (diphtheria, pertussis, and tetanus)/pentavalent vaccination, and there is a rapid decline of antibody levels between 12 and 35 months. We recommend that booster vaccination should be given at 12 to 15 months of age.

Keywords

pertussis - antibody - Nigeria
 

  • References

  • 1 Healy CM, Munoz FM, Rench MA, Halasa NB, Edwards KM, Baker CJ. Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis 2004; 190 (02) 335-340
    CrossrefPubMedGoogle Scholar
  • 2 Black RE, Cousens S, Johnson HL. , et al. Child Health Epidemiology Reference Group of WHO and UNICEF. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010; 375 (9730): 1969-1987
    CrossrefPubMedGoogle Scholar
  • 3 World Health Organization. World Health Statistics 2011. Geneva, Switzerland: World Health Organization: 2011
  • 4 Babaniji AO. Nigeria: how successful is the expanded program on immunization? An update. Trop Paediatr 1990; 36: 306-313
    PubMedGoogle Scholar
  • 5 Abdukarim AA, Ibrahim RM, Fawi AO, Adebayo AO, Johnson AWBR. Vaccines and immunization: the past, present and future in Nigeria. Niger J Paediatr 2011; 38 (04) 186-194
    PubMedGoogle Scholar
  • 6 GAVI, The Vaccine Alliance. Nigeria launches pentavalent vaccine. Available at: https://www.gavi.org/library/news/gavi-features/2012/nigeria-launches-pentavalent-vaccine/ . Accessed September 2015
    PubMed
  • 7 National Population Commission (NPC), Federal Republic of Nigeria, ICF international Nigeria Demographic and Health Survey 2013. Available at: https://dhsprogram.com/pubs/pdf/FR293/FR293.pdf . Accessed September 2015
    PubMed
  • 8 PAN Paediatric Association of Nigeria. Paediatrics Association of Nigeria recommended routine immunization schedule for Nigerian children. Niger J Paediatr 2012; 39 (04) 152-158
    PubMedGoogle Scholar
  • 9 de Melker HE, Versteegh FG, Conyn-Van Spaendonck MA. , et al. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J Clin Microbiol 2000; 38 (02) 800-806
    CrossrefPubMedGoogle Scholar
  • 10 Durpektova M, Hrstkova H. Is the level of IgG antibodies against pertussis toxin sufficient in vaccinated child population?. Scripta Medica 2008; 81 (02) 97-104
    PubMedGoogle Scholar
  • 11 Zepp F, Heininger U, Mertsola J. , et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis 2011; 11 (07) 557-570
    CrossrefPubMedGoogle Scholar
  • 12 National Population Commission. Census 2006 Final Results, Cross River State. Federal Republic of Nigeria Official Gazette, Abuja 2009;96:B1-B42. Available at: https://allafrica.com/stories/200705240129.html . Accessed July 8, 2019
    PubMed
  • 13 Bostoen K, Chalabi Z. Optimization of household survey sampling without sample frames. Int J Epidemiol 2006; 35 (03) 751-755
    CrossrefPubMedGoogle Scholar
  • 14 Bordetella pertussis toxin IgG (DRG instruments, GmbH, Germany). Available at: https://www.drg-diagnostics.de/ . Accessed September 20, 2015
    PubMed
  • 15 Vatansever U, Cöplü N, Oner N. , et al. Seroprevalance of Bordetella pertussis antibodies among healthy adolescent girls in Edirne. Swiss Med Wkly 2005; 135 (35,36): 531-536
    PubMedGoogle Scholar
  • 16 Jõgi P, Oona M, Toompere K, Leedo S, Epstein J, Lutsar I. Seroprevalence of IgG antibodies to pertussis toxin in children and adolescents in Estonia. Vaccine 2014; 32 (41) 5311-5315
    CrossrefPubMedGoogle Scholar
  • 17 Fadugba OO, Wang L, Chen Q, Halasa NB. Immune responses to pertussis antigens in infants and toddlers after immunization with multicomponent acellular pertussis vaccine. Clin Vaccine Immunol 2014; 21 (12) 1613-1619
    CrossrefPubMedGoogle Scholar
  • 18 de Greeff SC, Mooi FR, Westerhof A. , et al. Pertussis disease burden in the household: how to protect young infants. Clin Infect Dis 2010; 50 (10) 1339-1345
    CrossrefPubMedGoogle Scholar
  • 19 Tondella ML, Carlone GM, Messonnier N. , et al. International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georgia, United States, 19-20 July 2007. Vaccine 2009; 27 (06) 803-814
    CrossrefPubMedGoogle Scholar
  • 20 2 Oyefolu AOB, Nwaeke AC, Audu RA. , et al. Evaluation of measles vaccine cold chain in Lagos State, Nigeria. Afr J Clin Exp Microbiol 2007; 8: 1-7
    PubMedGoogle Scholar
  • 21 IVAC. Landscape analysis of routine immunization in Nigeria, 2012 . Available at: www.jhsph.edu/ivac . Accessed November 27, 2018
    PubMed
  • 22 Gaayeb L, Sarr JB, Ndiath MO. , et al. Seroprevalence of pertussis in Senegal: a prospective study. PLoS One 2012; 7 (10) e48684
    CrossrefPubMedGoogle Scholar
  • 23 Grimprel E, Bégué P, Anjak I, Njamkepo E, François P, Guiso N. Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France. Clin Diagn Lab Immunol 1996; 3 (01) 93-97
    CrossrefPubMedGoogle Scholar
  • 24 Muhammed AS, Wagas A, Aisha N, Habib B. Seroprevalence of Bordetella pertussis antibodies to pertussis toxin among healthy children. J Coll Phys Surg Pak 2012; 22: 677-678
    PubMedGoogle Scholar
  • 25 Ozkal A, Sensoy G, Acuner C, Belet N, Güney AK. Seroprevalence of Bordetella pertussis immunoglobulin G antibodies among children in Samsun, Turkey. Turk J Pediatr 2012; 54 (01) 15-19
    PubMedGoogle Scholar
  • 26 WHO. Pertussis vaccines: WHO position paper - September 2015. Wkly Epidemiol Rec 2015; 90 (35) 433-458
    PubMedGoogle Scholar
  • 27 Oloyede IS, Ekanem AM, Udo EE. Pattern of childhood pertussis in a tertiary hospital in Nigeria: a five year review (2007–2011). Niger J Paediatr 2015; 42: 83-87
    PubMedGoogle Scholar
  • 27 Omang HM. Post vaccination evaluation and molecular diagnosis of pertussis in Calabar, Nigeria. PhD Thesis, University of Calabar, Calabar Nigeria, 2016
    PubMedGoogle Scholar